This inventor holds 1 USPTO granted patent. Top assignee: Cenix Bioscience Gmbh. Active years: 2008.
Company Filing History:
Years Active: 2008
Title: Pierre Goenczy: Innovator in Eukaryotic Cell Division
Introduction
Pierre Goenczy is a notable inventor based in Lausanne, Switzerland. He has made significant contributions to the field of cell biology, particularly in understanding the mechanisms of eukaryotic cell division. His work has implications for diagnosing and treating proliferative diseases, showcasing the intersection of innovation and healthcare.
Latest Patents
Pierre Goenczy holds a patent related to "Eukaryotic cell division genes and their use in diagnosis and treatment of proliferative diseases." This invention highlights the functional role of several genes and their corresponding gene products in cell division and proliferation processes. The patent emphasizes the identification of functional orthologues of these genes through RNA-mediated interference (RNAi). Furthermore, it discusses the potential applications of these gene products in developing anti-proliferative agents and their use in screening assays for diagnosing and treating proliferative diseases. He has 1 patent to his name.
Career Highlights
Pierre Goenczy is associated with Cenix Bioscience GmbH, where he continues to advance research in cell biology. His work at this company has positioned him as a key figure in the scientific community, contributing to innovative solutions in the field.
Collaborations
Throughout his career, Pierre has collaborated with esteemed colleagues such as Christophe Echeverri and Anthony A Hyman. These collaborations have enriched his research and expanded the impact of his work in the scientific community.
Conclusion
Pierre Goenczy's contributions to the understanding of eukaryotic cell division and his innovative patent demonstrate his commitment to advancing medical science. His work not only enhances our understanding of cellular processes but also paves the way for new therapeutic approaches to combat proliferative diseases.